BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 109 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $65,621 | -64.3% | 9,853 | 0.0% | 0.00% | -100.0% |
| Q1 2023 | $183,857 | -13.1% | 9,853 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $211,642 | +81.7% | 9,853 | 0.0% | 0.00% | +100.0% |
| Q3 2022 | $116,462 | -10.5% | 9,853 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $130,060 | -36.9% | 9,853 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $206,026 | +61.5% | 9,853 | +57.0% | 0.00% | 0.0% |
| Q4 2021 | $127,591 | -33.0% | 6,276 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $190,477 | +33.1% | 6,276 | +27.5% | 0.00% | +100.0% |
| Q2 2021 | $143,091 | -32.7% | 4,924 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $212,520 | -6.6% | 4,924 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $227,489 | +6.5% | 4,924 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $213,505 | -18.2% | 4,924 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $261,021 | – | 4,924 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 550,000 | $23,848,000 | 3.05% |
| SPHERA FUNDS MANAGEMENT LTD. | 269,300 | $11,677,000 | 1.15% |
| Avidity Partners Management LP | 538,000 | $23,328,000 | 1.08% |
| Knoll Capital Management, LLC | 20,000 | $867,000 | 0.71% |
| Maven Securities LTD | 200,000 | $8,610,000 | 0.71% |
| Prosight Management, LP | 29,800 | $1,292,000 | 0.62% |
| Artemis Investment Management LLP | 1,001,708 | $43,383,000 | 0.54% |
| Ikarian Capital, LLC | 150,000 | $6,504,000 | 0.47% |
| AlphaCentric Advisors LLC | 20,000 | $867,000 | 0.42% |
| MOODY ALDRICH PARTNERS LLC | 19,872 | $862,000 | 0.18% |